Search for Clinical Trial Results

Sponsored By

Metastatic Squamous Neck Cancer With Occult Primary - 14 Studies Found

Status Study
Completed Study Name: SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
Condition: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Date: 2015-12-07
Interventions: Drug: SF1126
Completed Study Name: Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Condition:
  • Metastatic Squamous Neck Cancer With Occult Primary
  • Recurrent <
    Date: 2004-12-07
    Interventions:
    • Drug: lapatinib ditosylate Giv
Active, not recruiting Study Name: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Condition:
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • Biological: cetuximab Given IV
Completed Study Name: Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Condition:
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • Biological: cetuximab Given IV
Terminated Study Name: Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
Condition:
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • Drug: sunitinib malate Given o
Completed Study Name: S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Condition:
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • Drug: sorafenib tosylate Given
Active, not recruiting Study Name: PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Condition:
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • Drug: PI3K inhibitor BKM120 Gi
Completed Study Name: Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Condition:
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • Drug: dasatinib Given PO or vi
Completed Study Name: Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Condition:
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • Drug: ispinesib Given IV
Next >>>